S4.1.1-48. Savaysa [package insert] 2015. Daiichi Sankyo, Inc; Parsippany, NJ.S4.1.1-49. Nielsen PB, Skjøth F, Overvad TF, et al. Female sex is a risk modifier rather than a risk factor for stroke in atrial fibrillation: should we use a CHA2DS2-VA score rather than CHA2DS2-VASc? Circulation. 2018;137:832–40.S4.1.1-50. You JJ, Singer DE, Howard PA, et al. Antithrombotic therapy for atrial fibrillation: antithrombotic therapy and prevention of throm-bosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141:e531S–75.S4.1.1-51. US Renal Data System. 2016 USRDS annual data report: epidemiol-ogy of kidney disease in the United States. Bethesda, MD. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2016.S4.1.1-52. Sood MM, Komenda P, Sood AR, et al. The intersection of risk and benefit: is warfarin anticoagulation suitable for atrial fibrillation in patients on hemodialysis? Chest. 2009;136:1128–33.S4.1.1-53. Nochaiwong S, Ruengorn C, Awiphan R, et al. Efficacy and safety of warfarin in dialysis patients with atrial fibrillation: a systematic review and meta-analysis. Open Heart. 2016;3:e000441.S4.1.1-54. Deal EN, Pope H, Ross W. Apixaban use among patients with severe renal impairment. Ann Pharmacother. 2014;48:1667.S4.1.1-55. Stanton BE, Barasch NS, Tellor KB. Comparison of the safety and effectiveness of apixaban versus warfarin in patients with severe renal impairment. Pharmacotherapy. 2017;37:412–9.S4.1.1-56. Mavrakanas TA, Samer CF, Nessim SJ, et al. Apixaban pharmacoki-netics at steady state in hemodialysis patients. J Am Soc Nephrol. 2017;28:2241–8.S4.1.1-57. Reed D, Palkimas S, Hockman R, et al. Safety and effectiveness of apixaban compared to warfarin in dialysis patients. Res Pract Thromb Haemost. 2018;2:291–8.S4.1.1-58. Fauchier L, Clementy N, Bisson A, et al. Should atrial fibrillation patients with only 1 nongender-related CHA2DS2-VASc risk factor be anticoagulated? Stroke. 2016;47:1831–6.S4.1.1-59. Dias C, Moore KT, Murphy J, et al. Pharmacokinetics, pharmacody-namics, and safety of single-dose rivaroxaban in chronic hemodialy-sis. Am J Nephrol. 2016;43:229–36.Downloaded from by on March 4, 2020
January et al 2019 Focused Update on Atrial FibrillationCirculation.2019;140:e125–e151. DOI: 10.1161/CIR.0000000000000665 July 9, 2019e145CLINICAL STATEMENTS AND GUIDELINESS4.1.1-60. De Vriese AS, Caluwé R, Bailleul E, et al. Dose-finding study of riva-roxaban in hemodialysis patients. Am J Kidney Dis. 2015;66:91–8.S4.1.1-61. Chan KE, Edelman ER, Wenger JB, et al. Dabigatran and rivaroxa-ban use in atrial fibrillation patients on hemodialysis. Circulation. 2015;131:972–9.S4.1.1-62. Van de Werf F, Brueckmann M, Connolly SJ, et al. A comparison of dabigatran etexilate with warfarin in patients with mechani-cal heart valves: the randomized, phase II study to evaluate the safety and pharmacokinetics of oral dabigatran etexilate in patients after heart valve replacement (RE-ALIGN). Am Heart J.